ESTRO 2022 - Abstract Book

S1062

Abstract book

ESTRO 2022

Results During the study period, 95 patients were treated with ST + RT, and 1873 with ST alone. After a median follow-up of 13.3 months, median OS was 20.2 and 16.8 months (p= .348), respectively, in the two groups. Among 1714 patients without brain metastasis (BM), similar patterns of OS were observed in patients treated with ST + RT, as compared to those treated with ST alone, being the median OS 21.9 and 18.5 months (p= .488), respectively. Conversely, patients with BM (n= 254) treated with RT exhibited a significant greater OS as compared to those treated with ST alone, being median OS 21.3 and 7.6 months (p< .001), respectively, corresponding to an adjusted HR of 0.48 (95% CI 0.32-0.70). This reduction in the risk of death was greater in patients treated with first-line TKI (adjusted HR= 0.45, 95% CI 0.26-0.76), while in the smaller sample of those treated with first-line Pembrolizumab was not statistically significant (adjusted HR=0.74, 95% CI 0.37-1.50) ( Figure 1 ).

Conclusion Real-world data represent a new reality to complement evidence from controlled randomized clinical trials. The current work represent an exploratory study and analyses on the second line therapy will follow. Our data suggest that in patients with a worse prognosis, as the ones with BM, RT brings an effective advantage in terms of OS that should be considered in clinical practice.

PO-1258 Patient-reported symptoms in lung cancer survivors after radiotherapy treatment

A. Lazo Prados 1 , J.C. Villén Villén 2 , A. Heredia Ciuró, 3 , L. López López 3 , M. Granados Santiago 3 , M.C. Valenza 3

1 H. U. San Cecilio, Radiation Oncology, Granada, Spain; 2 H. Regional, Radiation Oncology, Málaga, Spain; 3 Granada University, Physiotherapy, Granada, Spain Purpose or Objective Radiotherapy implies the apoptosis of tumoral cells but also normal cells due to the radiation toxicity, resulting in several side effects. Knowing the presence of these symptoms allow an improvement in the global approach of these patients. The aim of this study was to evaluate the presence of patient-reported symptoms in lung cancer survivors after completing radiotherapy treatment. Materials and Methods In this observational study, lung cancer survivors with different stage treated with radiotherapy were included. These patients were evaluated one year after completing the radiotherapy treatment, and they were compared to a healthy control group matched by age and gender. This study evaluated the presence of different reported symptoms: dyspnea, fatigue, cough and health status. Dyspnea was evaluated with the Borg scale, fatigue was measured with Fatigue Severity Scale (FSS), cough with Cough Assessment Test (COAT), and health Status was evaluated with a Visual Analog Scale (VAS). Results A total of 56 patients and 56 controls were included in this study. Results are presented in the following table: Table 1. Reported symptoms in the studied subjects